The Peptide Field. Gonadorelin: approval and evidence record.

Editorial review: 2026-08-30. Dataset version: 2026-09-11.1.

https://thepeptidefield.com/peptides/gonadorelin

Lookup: https://thepeptidefield.com/peptide-evidence-checker?peptide=gonadorelin#result

This is a dated editorial summary, not a live FDA check or independent medical review. It does not recommend treatment or verify a product in hand.

Status: Former human products were FDA-approved; current human drug records list Factrel and Lutrepulse as discontinued

Exact product limits: FDA once approved human products named Factrel and Lutrepulse. Current human drug records list both as discontinued. FDA also lists current cattle products, including a separate Factrel product. Animal approval does not apply to people. A compounded or online product needs its own review.

Human outcomes: Moderate. Human studies measured ovulation and sperm development in people with defined hormone disorders. They do not establish broad fertility or testosterone benefits.

Body effects in people: Moderate. Human studies show that gonadorelin can trigger reproductive hormone signals in selected disorders and controlled settings.

What the evidence shows: FDA approved Factrel and Lutrepulse for people. Current records list both as discontinued. Lutrepulse was approved for women with hypothalamic amenorrhea, which can stop periods when the brain sends too little GnRH. Studies used a pump to copy the body's normal signal pattern. One study of 109 women found ovulation in more than 9 in 10. A study of 28 men was not randomized. It found earlier sperm development with the pump, but the overall rate was not clearly different.

What remains unknown: These studies did not test gonadorelin during testosterone therapy. They do not show that taking it from time to time protects fertility. They do not show a general testosterone benefit for men without the studied disorders. A compounded or online product is not proven to match former human products or study material. Current FDA-approved animal gonadorelin products are not approved for people.

Safety limits: FDA records and a 2026 warning letter show that each product has its own status. Approval for an animal or a former human product does not approve an online or compounded product for people. This guide gives no dosing, sourcing, injection, fertility, or testosterone-treatment instructions.

Approval claim: “Gonadorelin has never been FDA-approved for people.”
Verdict: Misleading. FDA approved Factrel and Lutrepulse for human uses. Current Drugs@FDA records list both products as discontinued. That history does not mean that a current gonadorelin product is approved.
Evidence basis: Regulatory or product record. Scope: Former U.S. human products and current U.S. human drug records as reviewed August 30, 2026.
Claim sources: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018123 https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019687 https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=17086

Approval claim: “Current animal gonadorelin products are FDA-approved for people.”
Verdict: Misleading. FDA lists current gonadorelin products for cattle. Their animal approvals do not approve them for people. One cattle product also uses the Factrel name, but it is not the former human Factrel product.
Evidence basis: Regulatory or product record. Scope: Current FDA-approved animal products for cattle, not human products.
Claim sources: https://www.fda.gov/animal-veterinary/product-safety-information/cattle-estrous-cycle-and-fda-approved-animal-drugs-control-and-synchronize-estrus-resource-producers

Sources used in the full review (a source is not support for every claim):

U.S. Food and Drug Administration Global Substance Registration System. Gonadorelin substance identity record (UNII 9O7312W37G). 2026. Accessed 2026-08-30. https://precision.fda.gov/uniisearch/srs/unii/9O7312W37G

U.S. Food and Drug Administration. FACTREL (gonadorelin) Drugs@FDA record, NDA 018123. 1982. Accessed 2026-08-30. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018123

U.S. Food and Drug Administration. LUTREPULSE KIT (gonadorelin) Drugs@FDA record, NDA 019687. 1989. Accessed 2026-08-30. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019687

U.S. Food and Drug Administration. Lutrepulse orphan-drug approval record. 1989. Accessed 2026-08-30. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=17086

U.S. Food and Drug Administration. Cattle estrous-cycle resource and FDA-approved animal drugs. 2026. Accessed 2026-08-30. https://www.fda.gov/animal-veterinary/product-safety-information/cattle-estrous-cycle-and-fda-approved-animal-drugs-control-and-synchronize-estrus-resource-producers

DailyMed · U.S. National Library of Medicine. FACTREL cattle product label and gonadorelin identity. 2026. Accessed 2026-08-30. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1451663c-b85a-4b45-8b27-6d572d0032f9

U.S. Food and Drug Administration. Wholesale Peptide warning letter. 2026. Accessed 2026-08-30. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wholesale-peptide-729447-06172026

U.S. Food and Drug Administration. Human drug compounding: FDA questions and answers. 2026. Accessed 2026-08-30. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

ClinicalTrials.gov. Gonadorelin study in hypogonadotropic hypogonadism. 2026. Accessed 2026-08-30. https://clinicaltrials.gov/study/NCT01976728

PubMed. Gonadorelin treatment in hypothalamic amenorrhea. 1986. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/3079597/

PubMed. Lutrepulse study in women with hypothalamic amenorrhea. 1990. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/2122733/

PubMed. Nonrandomized gonadorelin study in congenital hypogonadotropic hypogonadism. 2019. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/30569789/

World Anti-Doping Agency. 2026 Prohibited List. 2026. Accessed 2026-08-30. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf

Keep the limits, review date, and sources with this record. Check the current source for changes.